(Q37823555)

23 August 2017

1 reference

title

A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection (English)

1 reference

23 August 2017

1 reference

1 reference

Josephine Mauskopf

1

1 reference

23 August 2017

Lieven Annemans

series ordinal

2

1 reference

23 August 2017

Andrew M Hill

series ordinal

3

1 reference

23 August 2017

Erik Smets

series ordinal

4

1 reference

23 August 2017

publication date

1 January 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

28 Suppl 1

1 reference

23 August 2017

page(s)

1-16

1 reference

https://scigraph.springernature.com/pub.10.2165/11587410-000000000-00000

23 August 2017

exact match

0 references

cites work

Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

The impact of disease stage on direct medical costs of HIV management: a review of the international literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

The cost effectiveness of combination antiretroviral therapy for HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Meeting the NICE requirements: a Markov model approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Willingness to pay for a quality-adjusted life year: in search of a standard

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

The cost-effectiveness of the use of clopidogrel in acute coronary syndromes in five countries based upon the CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

How do we evaluate the economics of health care?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

A cost-effectiveness analysis of first-line controller therapies for persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

The CD4 lymphocyte count and risk of clinical progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Are we spending too much on HIV?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Are we spending too much on HIV?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

The cost of HIV treatment and care. A global review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Benefits and concerns of simplification strategies in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587410-000000000-00000

[Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"]

21 January 2018

1 reference

12 December 2020

HIV antiretroviral treatment: early versus later.

1 reference

12 December 2020

Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

1 reference

12 December 2020

Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients

1 reference

12 December 2020

Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen

1 reference

12 December 2020

Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program.

1 reference

12 December 2020

Cost to achieve an undetectable viral load using recommended antiretroviral regimens

1 reference

12 December 2020

Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature

1 reference

12 December 2020

[What is an efficient health technology in Spain?]

1 reference

12 December 2020

10.2165/11587410-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1035838110

0 references

1 reference